AMNEAL PHARMACEUTICALS, INC.
Moat Score — Amneal Pharmaceuticals, Inc.
Total Moat Score
9 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Amneal holds patents and formulation know-how protecting its Rytary and Crexont Parkinson's disease products, along with an extensive ANDA portfolio, though most of its generics business relies on off-patent, widely available formulations. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 2 / 5 | Amneal's vertically integrated manufacturing across U.S. and India facilities provides meaningful cost efficiency and supply chain control versus less-integrated generic competitors, though it competes against similarly scaled global generics giants like Teva and Viatris. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Amneal's specialty CNS franchise commands real branded pricing power, while its base generics business faces the same persistent commodity pricing pressure common across the broader generic pharmaceutical industry. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Pharmaceutical manufacturing and distribution exhibit no network effect; the value of Amneal's products to one customer does not increase because other customers also purchase them. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Neurologists and Parkinson's patients stabilized on Rytary or Crexont face real switching friction given titration sensitivity in movement disorder treatment, while base generic products face essentially no meaningful switching costs. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The broader generic pharmaceutical industry remains highly fragmented and competitive with many qualified manufacturers, so Amneal gains little efficient-scale protection outside of its more technically complex generic and specialty product niches. |